Biometry Research Group, National Cancer Institute, Bethesda, MD, USA.
Gynecol Oncol. 2012 Apr;125(1):70-4. doi: 10.1016/j.ygyno.2011.12.440. Epub 2011 Dec 22.
To determine whether CA-125 velocity is a statistically significant predictor of ovarian cancer and develop a classification rule to screen for ovarian cancer.
In the ovarian component of the PLCO cancer screening trial, 28,038 women aged 55-74 had at least two CA-125 screening tests. Ovarian cancer was diagnosed in 72 (0.26%) women. A multiple logistic regression model was developed to evaluate CA-125 velocity and other related covariates as predictors of ovarian cancer. Predictive accuracy was assessed by the concordance index and measures of discrimination and calibration while the fit of the model was assessed by the Hosmer and Lemeshow's goodness-of-fit χ(2)test.
CA-125 velocity decreased as the number of CA-125 measurements increased but was unaffected by age at baseline screen and family history of ovarian cancer. The average velocity (19.749U/ml per month) of the cancer group was more than 500 times the average velocity (0.035U/ml per month) of the non-cancer group.
Among six covariates used in the model, CA-125 velocity and time intervals between baseline and second to last screening test and between last two screening tests were statistically significant predictors of ovarian cancer. The chance of having ovarian cancer increased as velocity increased, and the chance decreased when the time intervals between baseline and the second to last screening test and between last two screening tests of an individual increased.
确定 CA-125 速度是否为卵巢癌的统计学显著预测因子,并制定用于筛查卵巢癌的分类规则。
在 PLCO 癌症筛查试验的卵巢部分中,共有 28038 名年龄在 55-74 岁的女性至少进行了两次 CA-125 筛查测试。72 名(0.26%)女性被诊断患有卵巢癌。建立了一个多变量逻辑回归模型,以评估 CA-125 速度和其他相关协变量作为卵巢癌的预测因子。通过一致性指数和判别和校准度量来评估预测准确性,同时通过 Hosmer 和 Lemeshow 的拟合优度 χ(2)检验评估模型的拟合情况。
CA-125 速度随着 CA-125 测量次数的增加而降低,但不受基线筛查时的年龄和卵巢癌家族史的影响。癌症组的平均速度(19.749U/ml 每月)是无癌组平均速度(0.035U/ml 每月)的 500 多倍。
在模型中使用的六个协变量中,CA-125 速度以及基线和倒数第二次筛查测试之间以及最后两次筛查测试之间的时间间隔是卵巢癌的统计学显著预测因子。随着速度的增加,患卵巢癌的机会增加,而个体从基线到倒数第二次筛查测试以及最后两次筛查测试之间的时间间隔增加时,机会减少。